Targeting Cytochrome P450 Enzymes in Ovarian Cancers: new approaches for Tumour-Selective Interventions
Authors:
- Yousef M. Al-SarairehYAYousef M. Al-Saraireh
- Fatemah O. F. O. AlshammariFAFatemah O. F. O. Alshammari
- Omar H. Abu-AzzamOAOmar H. Abu-Azzam
- Sa’Ed M. Al-DalainSASa’Ed M. Al-Dalain
- Yahya M. Al-SarayraYAYahya M. Al-Sarayra
- Mansour HaddadMHMansour Haddad
- Hafiz MakeenHMHafiz Makeen
- Aiman Al-QtaitatAAAiman Al-Qtaitat
- Mohammad AlmermeshMAMohammad Almermesh
- Sameeh A. Al-SarayrehSASameeh A. Al-Sarayreh
Preprint
- 4 September 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Over the past decade, significant developments have occurred in treatment strategies for ovarian cancer, yet targeted therapy with few side effects is still a major issue. The cytochrome P450 (CYP) enzyme family plays a vital role in the tumorigenesis process and metabolism of drugs, with a negative impact on therapy outcomes. Gaining more insight into CYP expression is crucial for understanding the pathophysiology of ovarian cancer since many isoforms are essential for the metabolism of xenobiotics and steroid hormones, which drive the disease's development. The purpose of this review is to provide a clear understanding of differential CYP expression in ovarian cancer and its implications for the prognosis of ovarian cancer patients, together with their polymorphisms' effect on chemotherapy metabolism. Finally, we provide our thoughts on opportunities to exploit metabolic CYP expression for novel therapeutic development to treat ovarian cancer.Keywords
All Related Versions
- Version 1, 2023-09-04, Preprints
- Published version: Biomedicines, 11 (11), 2898.
This publication has 83 references indexed in Scilit:
- Genetic variation of CYP3A5 influences paclitaxel/carboplatin‐induced toxicity in Chinese epithelial ovarian cancer patientsThe Journal of Clinical Pharmacology, 2015
- Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell linesMolecular and Cellular Biochemistry, 2013
- Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysisMolecular Biology Reports, 2012
- Impact of CYP3A5*3 and CYP2C8-HapC on Paclitaxel/Carboplatin-Induced Myelosuppression in Patients with Ovarian CancerJournal of Pharmaceutical Sciences, 2011
- Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancerCancer Causes & Control, 2008
- CYP1A1 Gene Polymorphism and Risk of Epithelial Ovarian NeoplasmGynecologic Oncology, 2002
- Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43Biochemical and Biophysical Research Communications, 2001
- CYP4B1 Is a Possible Risk Factor for Bladder Cancer in HumansBiochemical and Biophysical Research Communications, 2000
- Refinement of an ovarian cancer tumour suppressor gene locus on chromosome arm 22q and mutation analysis ofCYP2D6,SREBP2 andNAGAInternational Journal of Cancer, 2000
- CYP17 promotor polymorphism and ovarian cancer riskInternational Journal of Cancer, 2000